Abstract
Introduction: Diabetes, a global health issue, can cause diabetic nephropathy in one third of its sufferers. Recently, β-amyrin, a natural pentacyclic triterpene, has garnered interest for its potential to combat diabetes and treat chronic kidney disease resulting from the condition. In this study, we investigate the antihyperglycemic and renoprotective effects of β-amyrin, both individually and in combination with metformin, through the use of NRK-52E cell lines. Methods: We conducted an investigation into the impact of β-amyrin and metformin, both separately and in combination, on NRK-52E cell lines under normoglycemic and hyperglycemic conditions. High glucose-cotreated NRK-52E cells were exposed to these compounds, and their effects were evaluated through several parameters, including cell viability assessed using the cell counting kit-8 assay, apoptosis via flow cytometry, reactive oxygen species (ROS) levels using H2DCFDA expression, and gene expression studies via RT-qPCR to examine endoplasmic reticulum (ER) stress, apoptotic markers, and inflammatory markers. Results: Under normoglycemic conditions, the test compounds did not exhibit a significant impact on the cell lines. However, in the presence of high glucose, β-amyrin, metformin, and their combination demonstrated a noteworthy improvement in cell viability, with the combined treatment yielding superior results compared to individual treatments. The flow cytometry analysis revealed a substantial reduction in apoptotic cells, particularly with the combination treatment (p < 0.05). Moreover, the test compounds effectively inhibited high glucose-induced ROS production, with the combination treatment displaying the most significant reduction. Gene expression studies demonstrated a downregulation of ER stress, apoptotic markers, and inflammatory markers, with the combination treatment consistently yielding the greatest reductions. Conclusions: β-amyrin and metformin exhibit renoprotective effects in high glucose-induced renal cells, suggesting a promising therapeutic approach for mitigating hyperglycemia’s adverse effects on renal function. Further research in diabetic patients is needed to validate these findings.
Author Contributions
Conceptualization, Methodology, Investigation, Data curation, Software, Formal analysis, Visualization, Project administration, Resources, Supervision, Writing—original draft, review & editing, T.F.R.; Supervision, Conceptualization, Methodology, Writing review & editing, K.L.K. All authors have read and agreed to the published version of the manuscript.
Funding
This research received no external funding.
Institutional Review Board Statement
Not applicable.
Informed Consent Statement
Not applicable.
Data Availability Statement
Data sharing is not applicable due to privacy.
Conflicts of Interest
The authors declare no conflict of interest.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).